Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 134

1.

Five-year refracture rates of a province-wide fracture liaison service.

Sujic R, Beaton DE, Mamdani M, Cadarette SM, Luo J, Jaglal S, Sale JEM, Jain R, Bogoch E; Ontario Osteoporosis Strategy Fracture Screening and Prevention Program Evaluation Team.

Osteoporos Int. 2019 May 31. doi: 10.1007/s00198-019-05017-3. [Epub ahead of print]

PMID:
31152183
2.

Evidence of patient beliefs, values, and preferences is not provided in osteoporosis clinical practice guidelines.

Sale JEM, Marwah A, Naeem F, Yu W, Meadows L.

Osteoporos Int. 2019 Mar 11. doi: 10.1007/s00198-019-04913-y. [Epub ahead of print] Review.

PMID:
30859238
3.

Replication of G Quadruplex DNA.

Lerner LK, Sale JE.

Genes (Basel). 2019 Jan 29;10(2). pii: E95. doi: 10.3390/genes10020095. Review.

4.

Development process and patient usability preferences for a touch screen tablet-based questionnaire.

Lam Shin Cheung V, Kastner M, Sale JE, Straus S, Kaplan A, Boulet LP, Gupta S.

Health Informatics J. 2019 Jan 23:1460458218824749. doi: 10.1177/1460458218824749. [Epub ahead of print]

PMID:
30672358
5.

CtIP-BRCA1 complex and MRE11 maintain replication forks in the presence of chain terminating nucleoside analogs.

Mohiuddin M, Rahman MM, Sale JE, Pearson CE.

Nucleic Acids Res. 2019 Apr 8;47(6):2966-2980. doi: 10.1093/nar/gkz009.

6.

R-loop formation during S phase is restricted by PrimPol-mediated repriming.

Šviković S, Crisp A, Tan-Wong SM, Guilliam TA, Doherty AJ, Proudfoot NJ, Guilbaud G, Sale JE.

EMBO J. 2019 Feb 1;38(3). pii: e99793. doi: 10.15252/embj.201899793. Epub 2018 Nov 26.

7.

Treatment recommendations based on fracture risk status are not consistently provided in osteoporosis guidelines.

Sale JEM, Gray M, Mancuso D, Inrig T, Boire G, Beaulieu MC, Funnell L, Bogoch E.

Rheumatol Int. 2018 Dec;38(12):2193-2208. doi: 10.1007/s00296-018-4181-3. Epub 2018 Oct 26. Review.

PMID:
30367203
8.

Perceived Significance of Engagement in Research Prioritization Among Chronic Kidney Disease Patients, Caregivers, and Health Care Professionals: A Qualitative Study.

Elliott MJ, Goodarzi Z, Sale JEM, Wilhelm LA, Laupacis A, Hemmelgarn BR, Straus SE.

Can J Kidney Health Dis. 2018 Oct 19;5:2054358118807480. doi: 10.1177/2054358118807480. eCollection 2018.

9.

Identifying and Addressing Barriers to Osteoporosis Treatment Associated with Improved Outcomes: An Observational Cohort Study.

Rotondi NK, Beaton DE, Sujic R, Sale JEM, Ansari H, Elliot-Gibson V, Bogoch ER, Cullen J, Jain R, Slater M; and the Ontario Osteoporosis Strategy Fracture Clinic Screening Program Evaluation Team.

J Rheumatol. 2018 Nov;45(11):1594-1601. doi: 10.3899/jrheum.170915. Epub 2018 Sep 1.

PMID:
30173147
10.

Long-term views on chronic kidney disease research priorities among stakeholders engaged in a priority-setting partnership: A qualitative study.

Elliott MJ, Sale JEM, Goodarzi Z, Wilhelm L, Laupacis A, Hemmelgarn BR, Straus SE.

Health Expect. 2018 Dec;21(6):1142-1149. doi: 10.1111/hex.12818. Epub 2018 Aug 15.

11.

Patient preferences for a touch screen tablet-based asthma questionnaire.

Gupta S, Lam Shin Cheung V, Kastner M, Straus S, Kaplan A, Boulet LP, Sale JEM.

J Asthma. 2019 Jul;56(7):771-781. doi: 10.1080/02770903.2018.1490750. Epub 2018 Sep 28.

PMID:
29972087
12.

Qualitative research is a fundamental scientific process.

Sale JEM, Thielke S.

J Clin Epidemiol. 2018 Oct;102:129-133. doi: 10.1016/j.jclinepi.2018.04.024. Epub 2018 May 21.

PMID:
29793008
13.

A NuRD Complex from Xenopus laevis Eggs Is Essential for DNA Replication during Early Embryogenesis.

Christov CP, Dingwell KS, Skehel M, Wilkes HS, Sale JE, Smith JC, Krude T.

Cell Rep. 2018 Feb 27;22(9):2265-2278. doi: 10.1016/j.celrep.2018.02.015.

14.

Long-term experiences of pain after a fragility fracture.

Gheorghita A, Webster F, Thielke S, Sale JEM.

Osteoporos Int. 2018 May;29(5):1093-1104. doi: 10.1007/s00198-018-4399-7. Epub 2018 Feb 17.

PMID:
29455247
15.

Improvements in osteoporosis testing and care are found following the wide scale implementation of the Ontario Fracture Clinic Screening Program: An interrupted time series analysis.

Beaton DE, Mamdani M, Zheng H, Jaglal S, Cadarette SM, Bogoch ER, Sale JEM, Sujic R, Jain R; Ontario Osteoporosis Strategy Fracture Clinic Screening Program Evaluation Team.

Medicine (Baltimore). 2017 Dec;96(48):e9012. doi: 10.1097/MD.0000000000009012.

16.

Local epigenetic reprogramming induced by G-quadruplex ligands.

Guilbaud G, Murat P, Recolin B, Campbell BC, Maiter A, Sale JE, Balasubramanian S.

Nat Chem. 2017 Nov;9(11):1110-1117. doi: 10.1038/nchem.2828. Epub 2017 Jul 31.

17.

Equal treatment: no evidence of gender inequity in osteoporosis management in a coordinator-based fragility fracture screening program.

Ansari H, Beaton DE, Sujic R, Rotondi NK, Cullen JD, Slater M, Sale JEM, Jain R, Bogoch ER; Ontario Osteoporosis Strategy Fracture Screening and Prevention Program Evaluation Team.

Osteoporos Int. 2017 Dec;28(12):3401-3406. doi: 10.1007/s00198-017-4206-x. Epub 2017 Sep 10.

PMID:
28891035
18.

Pain and fracture-related limitations persist 6 months after a fragility fracture.

Sale JEM, Frankel L, Thielke S, Funnell L.

Rheumatol Int. 2017 Aug;37(8):1317-1322. doi: 10.1007/s00296-017-3761-y. Epub 2017 Jun 20.

PMID:
28634634
19.

The theory of planned behaviour explains intentions to use antiresorptive medication after a fragility fracture.

Sale JEM, Cameron C, Thielke S, Meadows L, Senior K.

Rheumatol Int. 2017 Jun;37(6):875-882. doi: 10.1007/s00296-017-3712-7. Epub 2017 Apr 18.

PMID:
28421359
20.

The dominant role of proofreading exonuclease activity of replicative polymerase ε in cellular tolerance to cytarabine (Ara-C).

Tsuda M, Terada K, Ooka M, Kobayashi K, Sasanuma H, Fujisawa R, Tsurimoto T, Yamamoto J, Iwai S, Kadoda K, Akagawa R, Huang SN, Pommier Y, Sale JE, Takeda S, Hirota K.

Oncotarget. 2017 May 16;8(20):33457-33474. doi: 10.18632/oncotarget.16508.

21.

The Effects of Replication Stress on S Phase Histone Management and Epigenetic Memory.

Šviković S, Sale JE.

J Mol Biol. 2017 Jun 30;429(13):2011-2029. doi: 10.1016/j.jmb.2016.11.011. Epub 2016 Nov 19. Review.

PMID:
27876548
22.

Addition of a fracture risk assessment to a coordinator's role improved treatment rates within 6 months of screening in a fragility fracture screening program.

Beaton DE, Vidmar M, Pitzul KB, Sujic R, Rotondi NK, Bogoch ER, Sale JEM, Jain R, Weldon J.

Osteoporos Int. 2017 Mar;28(3):863-869. doi: 10.1007/s00198-016-3794-1. Epub 2016 Oct 21.

PMID:
27770155
23.

Starting over: Primpol reprimes after chain termination.

Sale JE.

Cell Cycle. 2016 Aug 17;15(16):2099-2100. Epub 2016 Jul 6. No abstract available.

24.

Comparison of CAROC and FRAX in Fragility Fracture Patients: Agreement, Clinical Utility, and Implications for Clinical Practice.

Rotondi NK, Beaton DE, Elliot-Gibson V, Sujic R, Josse RG, Sale JE, Leslie WD, Bogoch ER.

J Rheumatol. 2016 Aug;43(8):1593-9. doi: 10.3899/jrheum.151409. Epub 2016 Jun 15.

PMID:
27307534
25.

Men's health-seeking behaviours regarding bone health after a fragility fracture: a secondary analysis of qualitative data.

Sale JE, Ashe MC, Beaton D, Bogoch E, Frankel L.

Osteoporos Int. 2016 Oct;27(10):3113-9. doi: 10.1007/s00198-016-3641-4. Epub 2016 May 27.

PMID:
27234669
26.

Histone H3.3 promotes IgV gene diversification by enhancing formation of AID-accessible single-stranded DNA.

Romanello M, Schiavone D, Frey A, Sale JE.

EMBO J. 2016 Jul 1;35(13):1452-64. doi: 10.15252/embj.201693958. Epub 2016 May 23.

27.

In vivo evidence for translesion synthesis by the replicative DNA polymerase δ.

Hirota K, Tsuda M, Mohiuddin, Tsurimoto T, Cohen IS, Livneh Z, Kobayashi K, Narita T, Nishihara K, Murai J, Iwai S, Guilbaud G, Sale JE, Takeda S.

Nucleic Acids Res. 2016 Sep 6;44(15):7242-50. doi: 10.1093/nar/gkw439. Epub 2016 May 16.

28.

Editorial.

Sale JE, Cox TM.

Expert Rev Mol Med. 2016 May 10;18:e10. doi: 10.1017/erm.2016.10. No abstract available.

PMID:
27160347
29.

The KRAB Zinc Finger Protein Roma/Zfp157 Is a Critical Regulator of Cell-Cycle Progression and Genomic Stability.

Ho TLF, Guilbaud G, Blow JJ, Sale JE, Watson CJ.

Cell Rep. 2016 Apr 26;15(4):724-734. doi: 10.1016/j.celrep.2016.03.078. Epub 2016 Apr 14.

30.

Targeting BRCA1 and BRCA2 Deficiencies with G-Quadruplex-Interacting Compounds.

Zimmer J, Tacconi EMC, Folio C, Badie S, Porru M, Klare K, Tumiati M, Markkanen E, Halder S, Ryan A, Jackson SP, Ramadan K, Kuznetsov SG, Biroccio A, Sale JE, Tarsounas M.

Mol Cell. 2016 Feb 4;61(3):449-460. doi: 10.1016/j.molcel.2015.12.004. Epub 2015 Dec 31.

31.

Nucleotide Pool Depletion Induces G-Quadruplex-Dependent Perturbation of Gene Expression.

Papadopoulou C, Guilbaud G, Schiavone D, Sale JE.

Cell Rep. 2015 Dec 22;13(11):2491-2503. doi: 10.1016/j.celrep.2015.11.039. Epub 2015 Dec 10.

32.

PrimPol Is Required for Replicative Tolerance of G Quadruplexes in Vertebrate Cells.

Schiavone D, Jozwiakowski SK, Romanello M, Guilbaud G, Guilliam TA, Bailey LJ, Sale JE, Doherty AJ.

Mol Cell. 2016 Jan 7;61(1):161-9. doi: 10.1016/j.molcel.2015.10.038. Epub 2015 Nov 25.

33.

Clock-like mutational processes in human somatic cells.

Alexandrov LB, Jones PH, Wedge DC, Sale JE, Campbell PJ, Nik-Zainal S, Stratton MR.

Nat Genet. 2015 Dec;47(12):1402-7. doi: 10.1038/ng.3441. Epub 2015 Nov 9.

34.

Bone Mineral Density Reporting Underestimates Fracture Risk in Ontario.

Sale JE, Bogoch E, Meadows L, Gignac M, Frankel L, Inrig T, Beaton D, Jain R.

Health (Irvine Calif). 2015 May;7(5):566-571.

35.

What Do We Know about Individuals Who Are Assessed as Being at Moderate Risk for Future Fracture in Canada?

Sale JE, Jain R, Akilan K, Senior K, Beaton D, Bogoch E, Boire G, Beaulieu MC, Lightfoot D, Funnell L.

Health (Irvine Calif). 2015 May;7(5):514-520.

36.

Directed evolution of human scFvs in DT40 cells.

Lim AW, Williams GT, Rada C, Sale JE.

Protein Eng Des Sel. 2016 Feb;29(2):39-48. doi: 10.1093/protein/gzv058. Epub 2015 Oct 30.

37.

A practical approach to evidence-based dentistry: VIII: How to appraise an article based on a qualitative study.

Sale JEM, Amin M, Carrasco-Labra A, Brignardello-Petersen R, Glick M, Guyatt GH, Azarpazhooh A.

J Am Dent Assoc. 2015 Aug;146(8):623-630. doi: 10.1016/j.adaj.2015.06.010.

PMID:
26227647
38.

Patients do not have a consistent understanding of high risk for future fracture: a qualitative study of patients from a post-fracture secondary prevention program.

Sale JE, Gignac MA, Hawker G, Beaton D, Frankel L, Bogoch E, Elliot-Gibson V.

Osteoporos Int. 2016 Jan;27(1):65-73. doi: 10.1007/s00198-015-3214-y. Epub 2015 Jun 27.

PMID:
26115943
39.

REV7/MAD2L2: the multitasking maestro emerges as a barrier to recombination.

Sale JE.

EMBO J. 2015 Jun 12;34(12):1609-11. doi: 10.15252/embj.201591697. Epub 2015 Apr 20. No abstract available.

40.

Ageism, negative attitudes, and competing co-morbidities--why older adults may not seek care for restricting back pain: a qualitative study.

Makris UE, Higashi RT, Marks EG, Fraenkel L, Sale JE, Gill TM, Reid MC.

BMC Geriatr. 2015 Apr 8;15:39. doi: 10.1186/s12877-015-0042-z.

41.

Contributions of the specialised DNA polymerases to replication of structured DNA.

Wickramasinghe CM, Arzouk H, Frey A, Maiter A, Sale JE.

DNA Repair (Amst). 2015 May;29:83-90. doi: 10.1016/j.dnarep.2015.01.004. Epub 2015 Feb 11. Review.

PMID:
25704659
42.

The POLD3 subunit of DNA polymerase δ can promote translesion synthesis independently of DNA polymerase ζ.

Hirota K, Yoshikiyo K, Guilbaud G, Tsurimoto T, Murai J, Tsuda M, Phillips LG, Narita T, Nishihara K, Kobayashi K, Yamada K, Nakamura J, Pommier Y, Lehmann A, Sale JE, Takeda S.

Nucleic Acids Res. 2015 Feb 18;43(3):1671-83. doi: 10.1093/nar/gkv023. Epub 2015 Jan 27.

43.

Histone H3.3 is required to maintain replication fork progression after UV damage.

Frey A, Listovsky T, Guilbaud G, Sarkies P, Sale JE.

Curr Biol. 2014 Sep 22;24(18):2195-2201. doi: 10.1016/j.cub.2014.07.077. Epub 2014 Sep 4.

44.

Determinants of G quadruplex-induced epigenetic instability in REV1-deficient cells.

Schiavone D, Guilbaud G, Murat P, Papadopoulou C, Sarkies P, Prioleau MN, Balasubramanian S, Sale JE.

EMBO J. 2014 Nov 3;33(21):2507-20. doi: 10.15252/embj.201488398. Epub 2014 Sep 4.

45.

Patient perceptions of provider barriers to post-fracture secondary prevention.

Sale JE, Bogoch E, Hawker G, Gignac M, Beaton D, Jaglal S, Frankel L.

Osteoporos Int. 2014 Nov;25(11):2581-9. doi: 10.1007/s00198-014-2804-4. Epub 2014 Aug 1.

PMID:
25082555
46.

Erratum to: Perceived messages about bone health after a fracture are not consistent across healthcare providers.

Sale JE, Hawker G, Cameron C, Bogoch E, Jain R, Beaton D, Jaglal S, Funnell L.

Rheumatol Int. 2015 Jan;35(1):105. doi: 10.1007/s00296-014-3090-3. No abstract available.

PMID:
25059574
47.

Perceived messages about bone health after a fracture are not consistent across healthcare providers.

Sale JE, Hawker G, Cameron C, Bogoch E, Jain R, Beaton D, Jaglal S, Funnell L.

Rheumatol Int. 2015 Jan;35(1):97-103. doi: 10.1007/s00296-014-3079-y. Epub 2014 Jun 25. Erratum in: Rheumatol Int. 2015 Jan;35(1):105.

PMID:
24962740
48.

Secondary prevention after an osteoporosis-related fracture: an overview.

Sale JE, Beaton D, Bogoch E.

Clin Geriatr Med. 2014 May;30(2):317-32. doi: 10.1016/j.cger.2014.01.009. Epub 2014 Mar 4. Review.

PMID:
24721371
49.

Retrospective. Michael Neuberger (1953-2013).

Sale JE, Patel KJ, Batista FD.

Science. 2013 Dec 13;342(6164):1335. doi: 10.1126/science.1248808. No abstract available.

PMID:
24337288
50.

Strategies used by an osteoporosis patient group to navigate for bone health care after a fracture.

Sale JE, Cameron C, Hawker G, Jaglal S, Funnell L, Jain R, Bogoch E.

Arch Orthop Trauma Surg. 2014 Feb;134(2):229-35. doi: 10.1007/s00402-013-1889-0. Epub 2013 Nov 26.

PMID:
24276358

Supplemental Content

Support Center